首页 > 最新文献

JTO Clinical and Research Reports最新文献

英文 中文
Treating Tobacco Dependency in National Health Service Workers in Greater Manchester: An Evaluation of a Bespoke Digital Service 治疗大曼彻斯特地区国家医疗服务系统工作人员的烟草依赖:对定制数字服务的评估
Q2 ONCOLOGY Pub Date : 2024-04-06 DOI: 10.1016/j.jtocrr.2024.100674
Kavita Sivabalah MB BCh BAO, MRCP (UK) , David Crane PhD , Samantha Neville , Mandy Hancock MSc , Anthony Ryan , Bincy Ajay , Jane Coyne BA , Elizabeth Benbow , Andrea Crossfield MSc , Sebastian Bate MMath , Matthew Evison MD

Introduction

Treating tobacco dependency in National Health Service (NHS) workers delivers substantial benefits at an individual, population, and health care system level. We report the outcomes from the Greater Manchester Integrated Care Partnership’s tobacco dependency treatment program for NHS workers which includes 6-months’ access to behavioral support and 12 weeks of treatment through a digital application.

Methods

Aggregate results for all participants across the program from January 1, 2022, to September 1, 2023, are reported including a deep-dive evaluation of 300 participants recruited to provide chemically validated outcomes.

Results

A total of 1567 NHS workers participated in the program within the evaluation period, completing 24,048 sessions with specialist advisors within the application, ordering 18,710 nicotine vape liquids, 6927 nicotine patches, and 297 short-acting nicotine products. Users reported achieving 89,464 smoke-free days, 1,258,069 less cigarettes smoked, and a financial saving of £622,231. The deep-dive evaluation revealed a CO-verified 12-week abstinence rate of 37% (111 of 300).

Conclusion

This evaluation provides assurance of clinical effectiveness within a bespoke digital tobacco dependency treatment program for NHS workers across an Integrated Care Partnership.

导言:治疗国民健康服务(NHS)工作人员的烟草依赖会在个人、人群和医疗保健系统层面带来巨大的益处。我们报告了大曼彻斯特地区综合医疗合作机构针对国家医疗服务体系工作人员开展的烟草依赖治疗项目的结果,该项目包括为期6个月的行为支持和12周的数字应用治疗。方法报告了2022年1月1日至2023年9月1日期间该项目所有参与者的综合结果,包括对招募的300名参与者进行的深入评估,以提供经化学验证的结果。结果在评估期间,共有 1567 名国家医疗服务系统工作人员参与了该计划,在应用程序中与专家顾问完成了 24,048 次对话,订购了 18,710 支尼古丁 vape 液体、6927 块尼古丁贴片和 297 件短效尼古丁产品。用户报告称,他们实现了 89,464 个无烟日,减少了 1,258,069 支香烟,节省了 622,231 英镑。深度评估显示,经 CO 验证的 12 周戒烟率为 37%(300 人中有 111 人戒烟)。
{"title":"Treating Tobacco Dependency in National Health Service Workers in Greater Manchester: An Evaluation of a Bespoke Digital Service","authors":"Kavita Sivabalah MB BCh BAO, MRCP (UK) ,&nbsp;David Crane PhD ,&nbsp;Samantha Neville ,&nbsp;Mandy Hancock MSc ,&nbsp;Anthony Ryan ,&nbsp;Bincy Ajay ,&nbsp;Jane Coyne BA ,&nbsp;Elizabeth Benbow ,&nbsp;Andrea Crossfield MSc ,&nbsp;Sebastian Bate MMath ,&nbsp;Matthew Evison MD","doi":"10.1016/j.jtocrr.2024.100674","DOIUrl":"10.1016/j.jtocrr.2024.100674","url":null,"abstract":"<div><h3>Introduction</h3><p>Treating tobacco dependency in National Health Service (NHS) workers delivers substantial benefits at an individual, population, and health care system level. We report the outcomes from the Greater Manchester Integrated Care Partnership’s tobacco dependency treatment program for NHS workers which includes 6-months’ access to behavioral support and 12 weeks of treatment through a digital application.</p></div><div><h3>Methods</h3><p>Aggregate results for all participants across the program from January 1, 2022, to September 1, 2023, are reported including a deep-dive evaluation of 300 participants recruited to provide chemically validated outcomes.</p></div><div><h3>Results</h3><p>A total of 1567 NHS workers participated in the program within the evaluation period, completing 24,048 sessions with specialist advisors within the application, ordering 18,710 nicotine vape liquids, 6927 nicotine patches, and 297 short-acting nicotine products. Users reported achieving 89,464 smoke-free days, 1,258,069 less cigarettes smoked, and a financial saving of £622,231. The deep-dive evaluation revealed a CO-verified 12-week abstinence rate of 37% (111 of 300).</p></div><div><h3>Conclusion</h3><p>This evaluation provides assurance of clinical effectiveness within a bespoke digital tobacco dependency treatment program for NHS workers across an Integrated Care Partnership.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 6","pages":"Article 100674"},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000444/pdfft?md5=7c3c7a54d194921b994c0771480aff7a&pid=1-s2.0-S2666364324000444-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart and Lung Dose as Predictors of Overall Survival in Patients With Locally Advanced Lung Cancer. A National Multicenter Study 预测局部晚期肺癌患者总生存期的心脏和肺部剂量。一项全国性多中心研究
Q2 ONCOLOGY Pub Date : 2024-04-01 DOI: 10.1016/j.jtocrr.2024.100663
Agon Olloni MD, PhD , Carsten Brink PhD , Ebbe Laugaard Lorenzen PhD , Stefan Starup Jeppesen PhD , Lone Hofmann PhD , Charlotte Kristiansen MD , Marianne Marquard Knap MD , Ditte Sloth Møller PhD , Lotte Nygård MD, PhD , Gitte Fredberg Persson MD, PhD , Rune Slot Thing PhD , Hella Maria Brøgger Sand MD , Axel Diederichsen MD, PhD , Tine Schytte MD, PhD

Introduction

It is an ongoing debate how much lung and heart irradiation impact overall survival (OS) after definitive radiotherapy for lung cancer. This study uses a large national cohort of patients with locally advanced NSCLC to investigate the association between OS and irradiation of lung and heart.

Methods

Treatment plans were acquired from six Danish radiotherapy centers, and patient characteristics were obtained from national registries. A hybrid segmentation tool automatically delineated the heart and substructures. Dose-volume histograms for all structures were extracted and analyzed using principal component analyses (PCAs). Parameter selection for a multivariable Cox model for OS prediction was performed using cross-validation based on bootstrapping.

Results

The population consisted of 644 patients with a median survival of 26 months (95% confidence interval [CI]: 24–29). The cross-validation selected two PCA variables to be included in the multivariable model. PCA1 represented irradiation of the heart and affected OS negatively (hazard ratio, 1.14; 95% CI: 1.04–1.26). PCA2 characterized the left-right balance (right atrium and left ventricle) irradiation, showing better survival for tumors near the right side (hazard ratio, 0.92; 95% CI: 0.84–1.00). Besides the two PCA variables, the multivariable model included age, sex, body-mass index, performance status, tumor dose, and tumor volume.

Conclusions

Besides the classic noncardiac risk factors, lung and heart doses had a negative impact on survival, while it is suggested that the left side of the heart is a more radiation dose–sensitive region. The data indicate that overall heart irradiation should be reduced to improve the OS if possible.

导言:肺部和心脏照射对肺癌明确放疗后的总生存期(OS)有多大影响一直是个争论不休的问题。本研究利用一个全国性的局部晚期 NSCLC 患者大型队列,研究 OS 与肺部和心脏照射之间的关系。方法治疗计划来自丹麦的 6 个放疗中心,患者特征来自全国性的登记资料。混合分割工具自动划分了心脏和亚结构。提取所有结构的剂量-体积直方图,并使用主成分分析法(PCA)进行分析。结果研究对象包括 644 名患者,中位生存期为 26 个月(95% 置信区间 [CI]:24-29)。交叉验证选择了两个PCA变量纳入多变量模型。PCA1 代表心脏的照射情况,对 OS 有负面影响(危险比为 1.14;95% CI:1.04-1.26)。PCA2 代表左右平衡(右心房和左心室)照射,显示靠近右侧的肿瘤生存率更高(危险比为 0.92;95% CI:0.84-1.00)。除了两个 PCA 变量外,多变量模型还包括年龄、性别、体重指数、表现状态、肿瘤剂量和肿瘤体积。这些数据表明,如果可能,应减少心脏的总体照射剂量,以提高生存率。
{"title":"Heart and Lung Dose as Predictors of Overall Survival in Patients With Locally Advanced Lung Cancer. A National Multicenter Study","authors":"Agon Olloni MD, PhD ,&nbsp;Carsten Brink PhD ,&nbsp;Ebbe Laugaard Lorenzen PhD ,&nbsp;Stefan Starup Jeppesen PhD ,&nbsp;Lone Hofmann PhD ,&nbsp;Charlotte Kristiansen MD ,&nbsp;Marianne Marquard Knap MD ,&nbsp;Ditte Sloth Møller PhD ,&nbsp;Lotte Nygård MD, PhD ,&nbsp;Gitte Fredberg Persson MD, PhD ,&nbsp;Rune Slot Thing PhD ,&nbsp;Hella Maria Brøgger Sand MD ,&nbsp;Axel Diederichsen MD, PhD ,&nbsp;Tine Schytte MD, PhD","doi":"10.1016/j.jtocrr.2024.100663","DOIUrl":"10.1016/j.jtocrr.2024.100663","url":null,"abstract":"<div><h3>Introduction</h3><p>It is an ongoing debate how much lung and heart irradiation impact overall survival (OS) after definitive radiotherapy for lung cancer. This study uses a large national cohort of patients with locally advanced NSCLC to investigate the association between OS and irradiation of lung and heart.</p></div><div><h3>Methods</h3><p>Treatment plans were acquired from six Danish radiotherapy centers, and patient characteristics were obtained from national registries. A hybrid segmentation tool automatically delineated the heart and substructures. Dose-volume histograms for all structures were extracted and analyzed using principal component analyses (PCAs). Parameter selection for a multivariable Cox model for OS prediction was performed using cross-validation based on bootstrapping.</p></div><div><h3>Results</h3><p>The population consisted of 644 patients with a median survival of 26 months (95% confidence interval [CI]: 24–29). The cross-validation selected two PCA variables to be included in the multivariable model. PCA1 represented irradiation of the heart and affected OS negatively (hazard ratio, 1.14; 95% CI: 1.04–1.26). PCA2 characterized the left-right balance (right atrium and left ventricle) irradiation, showing better survival for tumors near the right side (hazard ratio, 0.92; 95% CI: 0.84–1.00). Besides the two PCA variables, the multivariable model included age, sex, body-mass index, performance status, tumor dose, and tumor volume.</p></div><div><h3>Conclusions</h3><p>Besides the classic noncardiac risk factors, lung and heart doses had a negative impact on survival, while it is suggested that the left side of the heart is a more radiation dose–sensitive region. The data indicate that overall heart irradiation should be reduced to improve the OS if possible.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100663"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266636432400033X/pdfft?md5=e293483a3ddac4c0c51545322e9a2609&pid=1-s2.0-S266636432400033X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140280135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer 磷蛋白组学分析发现FAK和Src相互磷酸化是表皮生长因子受体突变肺癌对奥希替尼产生耐药性的机制之一
Q2 ONCOLOGY Pub Date : 2024-04-01 DOI: 10.1016/j.jtocrr.2024.100668
Takehiro Tozuka MD , Rintaro Noro MD, PhD , Keisuke Yoshida PhD , Satoshi Takahashi MD, PhD , Mariko Hirao XX , Kuniko Matsuda XX , Yasuhiro Kato MD , Shinji Nakamichi MD, PhD , Susumu Takeuchi MD, PhD , Masaru Matsumoto MD, PhD , Akihiko Miyanaga MD, PhD , Shinobu Kunugi MD, PhD , Kazufumi Honda DDS, PhD , Jun Adachi PhD , Masahiro Seike MD, PhD

Introduction

Osimertinib is a standard treatment for patients with EGFR-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non-genetic mechanisms underlying osimertinib resistance.

Methods

We established two osimertinib-resistant cell lines from EGFR mutation-positive PC-9 and HCC827 NSCLC cell lines (PC-9OR and HCC827OR, respectively) using a stepwise method. We compared the phosphoproteomic profiles of the osimertinib-resistant and parental cells using mass spectrometry. Upstream kinases were identified using the application Kinase Enrichment Analysis version 3.

Results

Phosphoproteomic analysis revealed 80 phosphorylation sites that were mutually up-regulated in PC-9OR and HCC827OR cells. The Kinase Enrichment Analysis version 3 analysis identified focal adhesion kinase (FAK) and proto-oncogene tyrosine-protein kinase Src (Src) as upstream kinases of these up-regulated phosphoproteins. The small-interfering RNA–mediated knockdown of FAK reduced Src phosphorylation and that of Src reduced FAK phosphorylation in both cell lines. Furthermore, FAK- or Src-specific small-interfering RNA treatments restored EGFR phosphorylation in PC-9OR and HCC827OR cells. The combination of FAK and Src inhibitors inhibited PC-9OR and HCC827OR cell proliferation in vitro and suppressed tumor growth in a xenograft mouse model. Immunohistochemistry of tumors from patients with EGFR-mutant NSCLC suggested that phosphorylated FAK and Src are involved in initial and acquired resistance to osimertinib.

Conclusions

Phosphoproteomic analysis may help elucidate the mechanisms of resistance to molecular-targeted therapies in lung cancer. Mutual phosphorylation of FAK and Src is involved in osimertinib resistance. Thus, FAK and Src inhibition may be novel treatment strategies for osimertinib-resistant NSCLC.

导言奥西替尼是治疗表皮生长因子受体突变型 NSCLC 患者的标准疗法。尽管已经发现了一些奥希替尼的耐药机制,但仍有近50%的机制有待阐明。本研究旨在确定奥希替尼耐药的非遗传机制。方法我们采用逐步法从表皮生长因子受体突变阳性的PC-9和HCC827 NSCLC细胞系中建立了两种奥希替尼耐药细胞系(分别为PC-9OR和HCC827OR)。我们使用质谱法比较了奥希替尼耐药细胞和亲代细胞的磷酸化蛋白质组谱。结果磷蛋白组学分析发现,PC-9OR和HCC827OR细胞中有80个磷酸化位点相互上调。Kinase Enrichment Analysis version 3分析确定了病灶粘附激酶(FAK)和原癌基因酪氨酸蛋白激酶Src(Src)是这些上调磷酸化蛋白的上游激酶。在这两种细胞系中,小干扰 RNA 介导的 FAK 敲除可减少 Src 磷酸化,而 Src 敲除可减少 FAK 磷酸化。此外,FAK或Src特异性小干扰RNA处理可恢复PC-9OR和HCC827OR细胞的表皮生长因子受体磷酸化。FAK和Src抑制剂的组合抑制了体外PC-9OR和HCC827OR细胞的增殖,并抑制了异种移植小鼠模型中肿瘤的生长。对表皮生长因子受体突变型 NSCLC 患者肿瘤的免疫组化结果表明,磷酸化的 FAK 和 Src 参与了奥希替尼的初始耐药性和获得性耐药性的产生。FAK和Src的相互磷酸化参与了奥希替尼的耐药性。因此,抑制FAK和Src可能是治疗奥希替尼耐药NSCLC的新策略。
{"title":"Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer","authors":"Takehiro Tozuka MD ,&nbsp;Rintaro Noro MD, PhD ,&nbsp;Keisuke Yoshida PhD ,&nbsp;Satoshi Takahashi MD, PhD ,&nbsp;Mariko Hirao XX ,&nbsp;Kuniko Matsuda XX ,&nbsp;Yasuhiro Kato MD ,&nbsp;Shinji Nakamichi MD, PhD ,&nbsp;Susumu Takeuchi MD, PhD ,&nbsp;Masaru Matsumoto MD, PhD ,&nbsp;Akihiko Miyanaga MD, PhD ,&nbsp;Shinobu Kunugi MD, PhD ,&nbsp;Kazufumi Honda DDS, PhD ,&nbsp;Jun Adachi PhD ,&nbsp;Masahiro Seike MD, PhD","doi":"10.1016/j.jtocrr.2024.100668","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100668","url":null,"abstract":"<div><h3>Introduction</h3><p>Osimertinib is a standard treatment for patients with <em>EGFR</em>-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non-genetic mechanisms underlying osimertinib resistance.</p></div><div><h3>Methods</h3><p>We established two osimertinib-resistant cell lines from <em>EGFR</em> mutation-positive PC-9 and HCC827 NSCLC cell lines (PC-9OR and HCC827OR, respectively) using a stepwise method. We compared the phosphoproteomic profiles of the osimertinib-resistant and parental cells using mass spectrometry. Upstream kinases were identified using the application Kinase Enrichment Analysis version 3.</p></div><div><h3>Results</h3><p>Phosphoproteomic analysis revealed 80 phosphorylation sites that were mutually up-regulated in PC-9OR and HCC827OR cells. The Kinase Enrichment Analysis version 3 analysis identified focal adhesion kinase (FAK) and proto-oncogene tyrosine-protein kinase Src (Src) as upstream kinases of these up-regulated phosphoproteins. The small-interfering RNA–mediated knockdown of FAK reduced Src phosphorylation and that of Src reduced FAK phosphorylation in both cell lines. Furthermore, FAK- or Src-specific small-interfering RNA treatments restored EGFR phosphorylation in PC-9OR and HCC827OR cells. The combination of FAK and Src inhibitors inhibited PC-9OR and HCC827OR cell proliferation in vitro and suppressed tumor growth in a xenograft mouse model. Immunohistochemistry of tumors from patients with <em>EGFR</em>-mutant NSCLC suggested that phosphorylated FAK and Src are involved in initial and acquired resistance to osimertinib.</p></div><div><h3>Conclusions</h3><p>Phosphoproteomic analysis may help elucidate the mechanisms of resistance to molecular-targeted therapies in lung cancer. Mutual phosphorylation of FAK and Src is involved in osimertinib resistance. Thus, FAK and Src inhibition may be novel treatment strategies for osimertinib-resistant NSCLC.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100668"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000389/pdfft?md5=7b6560c60e702d1983547e4ee3c5ef18&pid=1-s2.0-S2666364324000389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140550838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC 简要报告:免疫检查点抑制剂在局部晚期 NSCLC 患者中的临床疗效与输注时机有关
Q2 ONCOLOGY Pub Date : 2024-04-01 DOI: 10.1016/j.jtocrr.2024.100659
Tsuyoshi Hirata MD , Yuji Uehara MD , Taiki Hakozaki MD , Takayuki Kobayashi MD , Yuto Terashima MD , Kageaki Watanabe MD , Makiko Yomota MD, PhD , Yukio Hosomi MD, PhD

Introduction

Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcomes in patients with locally advanced NSCLC.

Methods

Patients receiving durvalumab after chemoradiotherapy for locally advanced NSCLC at a single institution were retrospectively analyzed, and the association of the proportion of durvalumab infusions greater than or equal to 20% versus less than 20% after 3 PM with progression-free survival (PFS) and overall survival was assessed.

Results

A total of 82 patients were included, with a median age of 69 years (interquartile range, 62–74 years); of these, 67 patients (82%) were of male sex, and 78 patients (95%) had a history of smoking. The median number of durvalumab infusions per patient was 16 (interquartile range, 8–24). Patients with at least 20% of their durvalumab infusions after 3 PM (n = 12/82, 15%) had a significantly shorter PFS than those who did not (median: 7.4 mo versus not available [NA]; hazard ratio [HR], 2.43; 95% confidence interval [CI]: 1.11–5.34, p = 0.027), whereas overall survival was shorter among the former compared with the latter group (median: 22.4 versus NA; HR, 1.80; 95% CI: 0.73–4.42, p = 0.20). In addition, both backward stepwise multivariable analysis and propensity score–matching analysis revealed that receiving at least 20% of durvalumab infusions after 3 PM was significantly associated with worse PFS (HR, 2.54; 95% CI: 1.03–5.67, p = 0.047; and HR, 4.64; 95% CI: 1.95–11.04; p < 0.001, respectively).

Conclusions

The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC.

导言先前的研究报道了免疫检查点抑制剂输注时机与转移性NSCLC治疗效果之间的关系。本研究评估了局部晚期NSCLC患者输注durvalumab的时间与生存结果之间的关系。方法回顾性分析了在一家机构接受化放疗后输注durvalumab的局部晚期NSCLC患者,并评估了下午3点后输注durvalumab的比例大于或等于20%与小于20%与无进展生存期(PFS)和总生存期之间的关系。结果 共纳入82名患者,中位年龄为69岁(四分位间范围为62-74岁);其中67名患者(82%)为男性,78名患者(95%)有吸烟史。每位患者的杜伐单抗输注次数中位数为16次(四分位间范围为8-24次)。下午 3 点后输注至少 20% 杜伐单抗的患者(n = 12/82,15%)的 PFS 明显短于未在下午 3 点后输注杜伐单抗的患者(中位数为 7.4 个月,无数据):中位数:7.4 个月,而无数据[NA];危险比[HR],2.43;95% 置信区间[CI]:1.11-5.34,p = 0.027),而前者的总生存期比后者短(中位数:22.4 个月比 NA;HR,1.80;95% 置信区间 [CI]:0.73-4.42,p = 0.20)。此外,后向逐步多变量分析和倾向得分匹配分析均显示,在下午3点后接受至少20%的杜伐单抗输注与较差的PFS显著相关(HR,2.54;95% CI:1.03-5.67,p = 0.047;HR,4.64;95% CI:1.95-11.04;p <0.001)。
{"title":"Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC","authors":"Tsuyoshi Hirata MD ,&nbsp;Yuji Uehara MD ,&nbsp;Taiki Hakozaki MD ,&nbsp;Takayuki Kobayashi MD ,&nbsp;Yuto Terashima MD ,&nbsp;Kageaki Watanabe MD ,&nbsp;Makiko Yomota MD, PhD ,&nbsp;Yukio Hosomi MD, PhD","doi":"10.1016/j.jtocrr.2024.100659","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100659","url":null,"abstract":"<div><h3>Introduction</h3><p>Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcomes in patients with locally advanced NSCLC.</p></div><div><h3>Methods</h3><p>Patients receiving durvalumab after chemoradiotherapy for locally advanced NSCLC at a single institution were retrospectively analyzed, and the association of the proportion of durvalumab infusions greater than or equal to 20% versus less than 20% after 3 <span>PM</span> with progression-free survival (PFS) and overall survival was assessed.</p></div><div><h3>Results</h3><p>A total of 82 patients were included, with a median age of 69 years (interquartile range, 62–74 years); of these, 67 patients (82%) were of male sex, and 78 patients (95%) had a history of smoking. The median number of durvalumab infusions per patient was 16 (interquartile range, 8–24). Patients with at least 20% of their durvalumab infusions after 3 <span>PM</span> (n = 12/82, 15%) had a significantly shorter PFS than those who did not (median: 7.4 mo versus not available [NA]; hazard ratio [HR], 2.43; 95% confidence interval [CI]: 1.11–5.34, <em>p</em> = 0.027), whereas overall survival was shorter among the former compared with the latter group (median: 22.4 versus NA; HR, 1.80; 95% CI: 0.73–4.42, <em>p</em> = 0.20). In addition, both backward stepwise multivariable analysis and propensity score–matching analysis revealed that receiving at least 20% of durvalumab infusions after 3 <span>PM</span> was significantly associated with worse PFS (HR, 2.54; 95% CI: 1.03–5.67, <em>p</em> = 0.047; and HR, 4.64; 95% CI: 1.95–11.04; <em>p</em> &lt; 0.001, respectively).</p></div><div><h3>Conclusions</h3><p>The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100659"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000298/pdfft?md5=d84cbc04706013262d06e8a2bc481903&pid=1-s2.0-S2666364324000298-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315) 在德国前瞻性 CRISP 登记处真实世界队列中对可能符合试验条件或不符合试验条件的转移性 NSCLC 患者进行检查点抑制剂单药治疗(AIO-TRK-0315)
Q2 ONCOLOGY Pub Date : 2024-04-01 DOI: 10.1016/j.jtocrr.2023.100626
Frank Griesinger MD, PhD , Martin Sebastian MD , Wolfgang M. Brueckl MD, PhD , Horst-Dieter Hummel MD, PhD , Bastian Jaeschke MD , Jens Kern MD , Claas Wesseler MD , Martina Jänicke PdD , Annette Fleitz PhD , Stefan Zacharias PhD , Annette Hipper PhD , Annika Groth MD, PhD , Wilko Weichert MD, PhD , Steffen Dörfel , Volker Petersen MD , Jan Schröder MD , Jochen Wilke MD , Wilfried E.E. Eberhardt MD, PhD , Michael Thomas MD, PhD , Matthias Zeth

Introduction

Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in real-world and to compare the outcome of “trial-ineligible” and “potentially trial-eligible” patients.

Methods

Data from the prospective, clinical research platform CRISP were used to compare patient characteristics, treatment, and outcome of patients with programmed cell death-ligand 1 tumor proportion score greater than or equal to 50% tumors treated with pembrolizumab monotherapy who are deemed either “potentially trial-eligible” or “trial-ineligible” according to inclusion and exclusion criteria of the registrational studies (KEYNOTE-024 and -042).

Results

Of 746 patients included, 343 patients (46.0%) were classified as “trial-ineligible” and had significantly worse outcomes compared with “potentially trial-eligible” patients (n = 403, 54.0%): median progression-free survival: 6.2 (95% confidence interval [CI]: 5.2–8.4) versus 10.3 (95% CI: 8.4–13.8) months, hazard ratio (trial-ineligible versus potentially trial-eligible) of 1.43 (95% CI: 1.19–1.72), p less than 0.001; median overall survival: 15.9 (95% CI: 11.4–20.3) versus 25.3 (95% CI: 19.8–30.4) months, hazard ratio of 1.36 (95% CI: 1.10–1.67), p equals 0.004.

Conclusions

Our data reveal that a considerable proportion of patients with mNSCLC are not eligible to participate in a clinical trial and were found to have worse outcomes than potentially trial-eligible patients, whose outcomes were comparable with those obtained from pivotal clinical trials. This is of substantial clinical relevance for physicians discussing outcomes to be expected with their patients and stresses the need for real-world effectiveness analyses.

导言:在临床实践中,接受免疫检查点抑制剂治疗的转移性 NSCLC(mNSCLC)患者往往不符合临床试验的严格纳入标准。我们的目的是评估在现实世界中接受 pembrolizumab 单药治疗的转移性 NSCLC 患者的试验资格,并比较 "不符合试验资格 "和 "可能符合试验资格 "患者的治疗效果。方法 使用前瞻性临床研究平台CRISP的数据,比较程序性细胞死亡配体1肿瘤比例评分大于或等于50%的肿瘤患者接受pembrolizumab单药治疗的患者特征、治疗和预后,根据注册研究(KEYNOTE-024和-042)的纳入和排除标准,这些患者被视为 "潜在符合试验条件 "或 "不符合试验条件".结果 在纳入的746例患者中,343例患者(46.结果 在纳入的746例患者中,有343例患者(46.0%)被归类为 "不符合试验条件",与 "可能符合试验条件 "的患者(n = 403,54.0%)相比,其预后明显较差:中位无进展生存期:6.2(95% 置信区间[CI]:5.2-8.4)个月对10.3(95% CI:8.4-13.8)个月,危险比(不符合试验条件对可能符合试验条件)为1.43(95% CI:1.19-1.72),P小于0.001;中位总生存期:15.结论我们的数据显示,相当一部分 mNSCLC 患者不符合参加临床试验的条件,他们的预后比可能符合试验条件的患者差,而后者的预后与关键临床试验的结果相当。这对医生与患者讨论预期疗效具有重要的临床意义,并强调了进行真实世界疗效分析的必要性。
{"title":"Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)","authors":"Frank Griesinger MD, PhD ,&nbsp;Martin Sebastian MD ,&nbsp;Wolfgang M. Brueckl MD, PhD ,&nbsp;Horst-Dieter Hummel MD, PhD ,&nbsp;Bastian Jaeschke MD ,&nbsp;Jens Kern MD ,&nbsp;Claas Wesseler MD ,&nbsp;Martina Jänicke PdD ,&nbsp;Annette Fleitz PhD ,&nbsp;Stefan Zacharias PhD ,&nbsp;Annette Hipper PhD ,&nbsp;Annika Groth MD, PhD ,&nbsp;Wilko Weichert MD, PhD ,&nbsp;Steffen Dörfel ,&nbsp;Volker Petersen MD ,&nbsp;Jan Schröder MD ,&nbsp;Jochen Wilke MD ,&nbsp;Wilfried E.E. Eberhardt MD, PhD ,&nbsp;Michael Thomas MD, PhD ,&nbsp;Matthias Zeth","doi":"10.1016/j.jtocrr.2023.100626","DOIUrl":"10.1016/j.jtocrr.2023.100626","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in real-world and to compare the outcome of “trial-ineligible” and “potentially trial-eligible” patients.</p></div><div><h3>Methods</h3><p>Data from the prospective, clinical research platform CRISP were used to compare patient characteristics, treatment, and outcome of patients with programmed cell death-ligand 1 tumor proportion score greater than or equal to 50% tumors treated with pembrolizumab monotherapy who are deemed either “potentially trial-eligible” or “trial-ineligible” according to inclusion and exclusion criteria of the registrational studies (KEYNOTE-024 and -042).</p></div><div><h3>Results</h3><p>Of 746 patients included, 343 patients (46.0%) were classified as “trial-ineligible” and had significantly worse outcomes compared with “potentially trial-eligible” patients (n = 403, 54.0%): median progression-free survival: 6.2 (95% confidence interval [CI]: 5.2–8.4) versus 10.3 (95% CI: 8.4–13.8) months, hazard ratio (trial-ineligible versus potentially trial-eligible) of 1.43 (95% CI: 1.19–1.72), <em>p</em> less than 0.001; median overall survival: 15.9 (95% CI: 11.4–20.3) versus 25.3 (95% CI: 19.8–30.4) months, hazard ratio of 1.36 (95% CI: 1.10–1.67), <em>p</em> equals 0.004.</p></div><div><h3>Conclusions</h3><p>Our data reveal that a considerable proportion of patients with mNSCLC are not eligible to participate in a clinical trial and were found to have worse outcomes than potentially trial-eligible patients, whose outcomes were comparable with those obtained from pivotal clinical trials. This is of substantial clinical relevance for physicians discussing outcomes to be expected with their patients and stresses the need for real-world effectiveness analyses.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100626"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001698/pdfft?md5=5b8cc1593fb9bfb461f4fe4c69a65c3a&pid=1-s2.0-S2666364323001698-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139191820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease 简要报告:无症状奥西美替尼诱发间质性肺病后,奥西美替尼与厄洛替尼再挑战导致间质性肺病复发的风险
Q2 ONCOLOGY Pub Date : 2024-04-01 DOI: 10.1016/j.jtocrr.2024.100648
Molly S.C. Li M.B.B.S. , Kirsty W.C. Lee MBChB , Kevin K.S. Mok MBChB , Herbert H.F. Loong M.B.B.S. , K.C. Lam MBChB , Florence S.T. Mok M.B.B.S. , Landon L. Chan MBChB , Y.M. Lau M.B.B.S. , K.P. Chan MBChB , Joyce T.Y. Ng MBChB , Wesley K.Y. Wong M.B.B.S. , Benjamin H.W. Lam M.B.B.S. , Allen C.C. Chen BM , Matthew M.P. Lee MBChB , Olivia H. Chen MD, PhD , Tony S.K. Mok MD

Introduction

Interstitial lung disease (ILD) is the most frequent cause of drug-related mortality from EGFR tyrosine kinase inhibitors (TKIs). Yet, for patients with symptomatic osimertinib-induced ILD, the risk of recurrent ILD associated with EGFR TKI rechallenge, either with osimertinib or another TKI, such as erlotinib, is unclear.

Methods

Retrospective study of 913 patients who received osimertinib treatment for EGFR mutation-positive NSCLC. Clinical characteristics, ILD treatment history, and subsequent anticancer therapy of patients with symptomatic osimertinib-induced ILD were collated. The primary end point was to compare the incidence of recurrent ILD with osimertinib versus erlotinib rechallenge.

Results

Of 913 patients, 35 (3.8%) had symptomatic osimertinib-induced ILD, of which 12 (34%), 15 (43%), and eight (23%) had grade 2, 3 to 4, and 5 ILD, respectively. On ILD recovery, 17 patients had EGFR TKI rechallenge with eight received osimertinib and nine received erlotinib. The risk of recurrent ILD was higher with osimertinib rechallenge than erlotinib (p = 0.0498). Of eight, five (63%) developed recurrent ILD on osimertinib rechallenge, including three patients with fatal outcomes. In contrast, only one of nine patients (11%) treated with erlotinib had recurrent ILD. Median time to second ILD occurrence was 4.7 (range 0.7–12) weeks. Median time-to-treatment failure of patients with erlotinib rechallenge was 13.2 months (95% confidence interval: 8.6–15.0).

Conclusions

The risk of recurrent ILD was considerably higher with osimertinib rechallenge than erlotinib. Osimertinib rechallenge should be avoided, whereas erlotinib may be considered in patients with symptomatic osimertinib-induced ILD.

导言间质性肺病(ILD)是表皮生长因子受体酪氨酸激酶抑制剂(TKI)导致药物相关死亡的最常见原因。然而,对于有症状的奥希替尼诱发的ILD患者来说,与EGFR TKI再挑战相关的ILD复发风险尚不清楚,无论是奥希替尼还是另一种TKI,如厄洛替尼。方法对913例接受奥希替尼治疗的EGFR突变阳性NSCLC患者进行了回顾性研究。整理了有症状的奥希替尼诱发 ILD 患者的临床特征、ILD 治疗史和后续抗癌治疗。结果 在913例患者中,35例(3.8%)有症状性奥司替尼诱导的ILD,其中分别有12例(34%)、15例(43%)和8例(23%)为2级、3至4级和5级ILD。在ILD康复后,17名患者进行了EGFR TKI再挑战,其中8人接受了奥希替尼治疗,9人接受了厄洛替尼治疗。与厄洛替尼相比,奥希替尼再挑战ILD的复发风险更高(p = 0.0498)。8名患者中,有5名(63%)在接受奥希替尼再挑战后出现了复发性ILD,其中3名患者出现了致命后果。相比之下,接受厄洛替尼治疗的9名患者中仅有1名(11%)复发了ILD。第二次ILD发生的中位时间为4.7周(0.7-12周)。厄洛替尼再治疗患者治疗失败的中位时间为13.2个月(95%置信区间:8.6-15.0)。应避免奥希替尼再治疗,而对于有症状的奥希替尼诱发的ILD患者,可以考虑使用厄洛替尼。
{"title":"Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease","authors":"Molly S.C. Li M.B.B.S. ,&nbsp;Kirsty W.C. Lee MBChB ,&nbsp;Kevin K.S. Mok MBChB ,&nbsp;Herbert H.F. Loong M.B.B.S. ,&nbsp;K.C. Lam MBChB ,&nbsp;Florence S.T. Mok M.B.B.S. ,&nbsp;Landon L. Chan MBChB ,&nbsp;Y.M. Lau M.B.B.S. ,&nbsp;K.P. Chan MBChB ,&nbsp;Joyce T.Y. Ng MBChB ,&nbsp;Wesley K.Y. Wong M.B.B.S. ,&nbsp;Benjamin H.W. Lam M.B.B.S. ,&nbsp;Allen C.C. Chen BM ,&nbsp;Matthew M.P. Lee MBChB ,&nbsp;Olivia H. Chen MD, PhD ,&nbsp;Tony S.K. Mok MD","doi":"10.1016/j.jtocrr.2024.100648","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100648","url":null,"abstract":"<div><h3>Introduction</h3><p>Interstitial lung disease (ILD) is the most frequent cause of drug-related mortality from EGFR tyrosine kinase inhibitors (TKIs). Yet, for patients with symptomatic osimertinib-induced ILD, the risk of recurrent ILD associated with EGFR TKI rechallenge, either with osimertinib or another TKI, such as erlotinib, is unclear.</p></div><div><h3>Methods</h3><p>Retrospective study of 913 patients who received osimertinib treatment for <em>EGFR</em> mutation-positive NSCLC. Clinical characteristics, ILD treatment history, and subsequent anticancer therapy of patients with symptomatic osimertinib-induced ILD were collated. The primary end point was to compare the incidence of recurrent ILD with osimertinib versus erlotinib rechallenge.</p></div><div><h3>Results</h3><p>Of 913 patients, 35 (3.8%) had symptomatic osimertinib-induced ILD, of which 12 (34%), 15 (43%), and eight (23%) had grade 2, 3 to 4, and 5 ILD, respectively. On ILD recovery, 17 patients had EGFR TKI rechallenge with eight received osimertinib and nine received erlotinib. The risk of recurrent ILD was higher with osimertinib rechallenge than erlotinib (<em>p</em> = 0.0498). Of eight, five (63%) developed recurrent ILD on osimertinib rechallenge, including three patients with fatal outcomes. In contrast, only one of nine patients (11%) treated with erlotinib had recurrent ILD. Median time to second ILD occurrence was 4.7 (range 0.7–12) weeks. Median time-to-treatment failure of patients with erlotinib rechallenge was 13.2 months (95% confidence interval: 8.6–15.0).</p></div><div><h3>Conclusions</h3><p>The risk of recurrent ILD was considerably higher with osimertinib rechallenge than erlotinib. Osimertinib rechallenge should be avoided, whereas erlotinib may be considered in patients with symptomatic osimertinib-induced ILD.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100648"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000183/pdfft?md5=a61f22993f5c7bf6be994155930c4030&pid=1-s2.0-S2666364324000183-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma 肿瘤免疫微环境与早期肺腺癌复发有关
Q2 ONCOLOGY Pub Date : 2024-04-01 DOI: 10.1016/j.jtocrr.2024.100658
Hiroaki Kanemura MD, MPH, PhD , Toshihide Yokoyama MD , Ryu Nakajima MD, PhD , Atsushi Nakamura MD, PhD , Hiroaki Kuroda MD, PhD , Yoshitaka Kitamura MD, PhD , Hiroyasu Shoda MD, PhD , Nobuaki Mamesaya MD, PhD , Yoshihiro Miyata MD, PhD , Tatsuro Okamoto MD, PhD , Kyoichi Okishio MD, PhD , Masahide Oki MD, PhD , Yuichi Sakairi MD, PhD , Toyofumi Fengshi Chen-Yoshikawa MD, PhD , Tadashi Aoki MD , Tatsuo Ohira MD, PhD , Isao Matsumoto MD, PhD , Kiyonobu Ueno MD, PhD , Takuro Miyazaki MD, PhD , Haruhisa Matsuguma MD, PhD , Masayuki Takeda MD, PhD

Introduction

Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence after adjuvant chemotherapy or who are likely to benefit from postoperative immunotherapy have remained unclear.

Methods

This biomarker study (WJOG12219LTR) was designed to evaluate cancer stem cell markers (CD44 and CD133), programmed death-ligand 1 (PD-L1) expression on tumor cells, CD8 expression on tumor-infiltrating lymphocytes, and tumor mutation burden in completely resected stage II to IIIA NSCLC with the use of archived DNA and tissue samples from the prospective WJOG4107 trial. Tumors were classified as inflamed or noninflamed on the basis of the PD-L1 tumor proportion score and CD8+ tumor-infiltrating lymphocyte density. The association between each potential biomarker and relapse-free survival (RFS) during adjuvant chemotherapy was assessed by Kaplan-Meier analysis.

Results

A total of 117 patients were included in this study. The median RFS was not reached (95% confidence intervals [CI]: 22.4 mo–not reached; n = 39) and 23.7 months (95% CI: 14.5–43.6; n = 41) in patients with inflamed or noninflamed adenocarcinoma, respectively (log-rank p = 0.02, hazard ratio of 0.52 [95% CI: 0.29–0.93]). Analysis of the combination of tumor inflammation category and TP53 mutation status revealed that inflamed tumors without TP53 mutations were associated with the longest RFS.

Conclusions

PD-L1 expression on tumor cells, CD8+ T cell infiltration, and TP53 mutation status may help identify patients with early-stage NSCLC susceptible to recurrence after adjuvant chemotherapy.

导言根据三期试验结果,免疫检查点抑制剂最近被批准用于治疗早期NSCLC围手术期患者。然而,辅助化疗后易复发或可能从术后免疫疗法中获益的这类患者的特征仍不清楚。方法这项生物标记物研究(WJOG12219LTR)旨在利用前瞻性WJOG4107试验的存档DNA和组织样本,评估完全切除的II期至IIIA期NSCLC的癌症干细胞标记物(CD44和CD133)、肿瘤细胞上的程序性死亡配体1(PD-L1)表达、肿瘤浸润淋巴细胞上的CD8表达和肿瘤突变负荷。根据PD-L1肿瘤比例评分和CD8+肿瘤浸润淋巴细胞密度将肿瘤分为炎症和非炎症。通过 Kaplan-Meier 分析评估了每个潜在生物标志物与辅助化疗期间无复发生存期(RFS)之间的关系。有炎症或无炎症腺癌患者的中位无复发生存期分别为未达到(95% 置信区间 [CI]:22.4 个月未达到;n = 39)和 23.7 个月(95% CI:14.5-43.6;n = 41)(log-rank p = 0.02,危险比为 0.52 [95% CI:0.29-0.93])。结论肿瘤细胞上PD-L1的表达、CD8+ T细胞浸润和TP53突变状态可能有助于识别辅助化疗后易复发的早期NSCLC患者。
{"title":"The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma","authors":"Hiroaki Kanemura MD, MPH, PhD ,&nbsp;Toshihide Yokoyama MD ,&nbsp;Ryu Nakajima MD, PhD ,&nbsp;Atsushi Nakamura MD, PhD ,&nbsp;Hiroaki Kuroda MD, PhD ,&nbsp;Yoshitaka Kitamura MD, PhD ,&nbsp;Hiroyasu Shoda MD, PhD ,&nbsp;Nobuaki Mamesaya MD, PhD ,&nbsp;Yoshihiro Miyata MD, PhD ,&nbsp;Tatsuro Okamoto MD, PhD ,&nbsp;Kyoichi Okishio MD, PhD ,&nbsp;Masahide Oki MD, PhD ,&nbsp;Yuichi Sakairi MD, PhD ,&nbsp;Toyofumi Fengshi Chen-Yoshikawa MD, PhD ,&nbsp;Tadashi Aoki MD ,&nbsp;Tatsuo Ohira MD, PhD ,&nbsp;Isao Matsumoto MD, PhD ,&nbsp;Kiyonobu Ueno MD, PhD ,&nbsp;Takuro Miyazaki MD, PhD ,&nbsp;Haruhisa Matsuguma MD, PhD ,&nbsp;Masayuki Takeda MD, PhD","doi":"10.1016/j.jtocrr.2024.100658","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100658","url":null,"abstract":"<div><h3>Introduction</h3><p>Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence after adjuvant chemotherapy or who are likely to benefit from postoperative immunotherapy have remained unclear.</p></div><div><h3>Methods</h3><p>This biomarker study (WJOG12219LTR) was designed to evaluate cancer stem cell markers (CD44 and CD133), programmed death-ligand 1 (PD-L1) expression on tumor cells, CD8 expression on tumor-infiltrating lymphocytes, and tumor mutation burden in completely resected stage II to IIIA NSCLC with the use of archived DNA and tissue samples from the prospective WJOG4107 trial. Tumors were classified as inflamed or noninflamed on the basis of the PD-L1 tumor proportion score and CD8<sup>+</sup> tumor-infiltrating lymphocyte density. The association between each potential biomarker and relapse-free survival (RFS) during adjuvant chemotherapy was assessed by Kaplan-Meier analysis.</p></div><div><h3>Results</h3><p>A total of 117 patients were included in this study. The median RFS was not reached (95% confidence intervals [CI]: 22.4 mo–not reached; n = 39) and 23.7 months (95% CI: 14.5–43.6; n = 41) in patients with inflamed or noninflamed adenocarcinoma, respectively (log-rank <em>p</em> = 0.02, hazard ratio of 0.52 [95% CI: 0.29–0.93]). Analysis of the combination of tumor inflammation category and <em>TP53</em> mutation status revealed that inflamed tumors without <em>TP53</em> mutations were associated with the longest RFS.</p></div><div><h3>Conclusions</h3><p>PD-L1 expression on tumor cells, CD8<sup>+</sup> T cell infiltration, and <em>TP53</em> mutation status may help identify patients with early-stage NSCLC susceptible to recurrence after adjuvant chemotherapy.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100658"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000286/pdfft?md5=d33532546693496a34f932f2317fecfb&pid=1-s2.0-S2666364324000286-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing Opportunity: Pilot Intervention to Improve Lung Cancer Screening for Women Undergoing Breast Screening Mammography 把握机遇:改善接受乳房 X 射线摄影筛查妇女肺癌筛查的试点干预措施
Q2 ONCOLOGY Pub Date : 2024-03-26 DOI: 10.1016/j.jtocrr.2024.100671
Lye-Yeng Wong MD , Tiffany Yue BS , Ghazal Aghagoli BS , Ioana Baiu MD , Laura Shula PA-C , Angela Lee NP , Natalie S. Lui MD , Leah M. Backhus MD, MPH

Introduction

The screening mammogram could be a “teachable moment” to improve lung cancer screening (LCS) uptake. The aim of our project was to combine patient self-referral with eligibility identification by providers as a two-pronged approach to increase rates of LCS among eligible women.

Methods

LCS education materials were created to stimulate patient education and encourage self-referral. Chart review of patients scheduled for screening mammography was performed to identify patients who met LCS criteria. The primary outcome was rate of acceptance of targeted interventions as measured by qualitative survey material and rate of LCS uptake.

Results

Between August 2022 and August 2023, 116 patients were identified by providers for potential eligibility for LCS and 34 patients (29.3%) deemed eligible based on the U.S. Preventative Services Task Force 2021 guidelines. There were 19 patients (56%) who completed LCS with three patients (16%) with screen-detected nodules that led to further workup. Post-implementation qualitative survey results reveal that 100% of the participants rated their shared decision-making visit experience as “very helpful” and 67% responded “very likely” to seek simultaneous breast and LCS in the future. Informational materials were rated as 80% favorable among all respondents; however, the rate of self-referral alone was 0%. The combined rates of eligible patients lost to follow-up or refusal was 24%.

Conclusion

The self-referral aspect of the intervention revealed that patients are unlikely to self-refer for LCS. Nevertheless, patients undergoing screening mammograms individually identified for LCS were very responsive to learning more about dual screening.

导言:乳房X光筛查可以成为提高肺癌筛查(LCS)接受率的 "教学时机"。我们的项目旨在将患者的自我转诊与医疗服务提供者的资格鉴定相结合,双管齐下提高符合条件的妇女的肺癌筛查率。对计划进行乳房 X 光筛查的患者进行病历审查,以确定符合 LCS 标准的患者。结果在 2022 年 8 月至 2023 年 8 月期间,医疗服务提供者确定了 116 名患者可能符合 LCS 的条件,根据美国预防服务工作组 2021 年指南,34 名患者(29.3%)被认为符合条件。有 19 名患者(56%)完成了 LCS,其中有 3 名患者(16%)因筛查发现结节而需要进一步检查。实施后的定性调查结果显示,100% 的参与者将他们的共同决策就诊经历评为 "非常有帮助",67% 的参与者表示 "非常有可能 "在未来同时进行乳腺和 LCS 检查。所有受访者对信息资料的好评率为 80%;然而,仅自我转诊率就达到了 0%。结论干预措施的自我转诊方面显示,患者不太可能自我转诊进行 LCS 检查。尽管如此,接受乳房 X 光筛查的患者对了解更多有关双重筛查的信息反应非常积极。
{"title":"Harnessing Opportunity: Pilot Intervention to Improve Lung Cancer Screening for Women Undergoing Breast Screening Mammography","authors":"Lye-Yeng Wong MD ,&nbsp;Tiffany Yue BS ,&nbsp;Ghazal Aghagoli BS ,&nbsp;Ioana Baiu MD ,&nbsp;Laura Shula PA-C ,&nbsp;Angela Lee NP ,&nbsp;Natalie S. Lui MD ,&nbsp;Leah M. Backhus MD, MPH","doi":"10.1016/j.jtocrr.2024.100671","DOIUrl":"10.1016/j.jtocrr.2024.100671","url":null,"abstract":"<div><h3>Introduction</h3><p>The screening mammogram could be a “teachable moment” to improve lung cancer screening (LCS) uptake. The aim of our project was to combine patient self-referral with eligibility identification by providers as a two-pronged approach to increase rates of LCS among eligible women.</p></div><div><h3>Methods</h3><p>LCS education materials were created to stimulate patient education and encourage self-referral. Chart review of patients scheduled for screening mammography was performed to identify patients who met LCS criteria. The primary outcome was rate of acceptance of targeted interventions as measured by qualitative survey material and rate of LCS uptake.</p></div><div><h3>Results</h3><p>Between August 2022 and August 2023, 116 patients were identified by providers for potential eligibility for LCS and 34 patients (29.3%) deemed eligible based on the U.S. Preventative Services Task Force 2021 guidelines. There were 19 patients (56%) who completed LCS with three patients (16%) with screen-detected nodules that led to further workup. Post-implementation qualitative survey results reveal that 100% of the participants rated their shared decision-making visit experience as “very helpful” and 67% responded “very likely” to seek simultaneous breast and LCS in the future. Informational materials were rated as 80% favorable among all respondents; however, the rate of self-referral alone was 0%. The combined rates of eligible patients lost to follow-up or refusal was 24%.</p></div><div><h3>Conclusion</h3><p>The self-referral aspect of the intervention revealed that patients are unlikely to self-refer for LCS. Nevertheless, patients undergoing screening mammograms individually identified for LCS were very responsive to learning more about dual screening.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 6","pages":"Article 100671"},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000419/pdfft?md5=3b5d1bb05b435fdd0c1018b1f30bbc6f&pid=1-s2.0-S2666364324000419-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140406595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study 曾接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者使用卡博替尼加阿特珠单抗还是单用卡博替尼?COSMIC-021 1b 期研究结果
IF 3 Q2 ONCOLOGY Pub Date : 2024-03-20 DOI: 10.1016/j.jtocrr.2024.100666

Introduction

We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI).

Methods

COSMIC-021 (NCT03170960) is a phase 1b, multicenter study in advanced solid tumors. This analysis included patients with stage IV non-squamous NSCLC without actionable genomic aberrations in EGFR, ALK, ROS1, or BRAF-V600E who progressed on one prior ICI and less than or equal to two prior lines of systemic anticancer therapy. Patients received cabozantinib 40 mg orally/day plus atezolizumab 1200 mg intravenously every three weeks (combination cohort) or cabozantinib 60 mg orally/day (single-agent cabozantinib cohort). Primary end point of the combination cohort was objective response rate per Response Evaluation Criteria in Solid Tumors v1.1 by investigator. Outcomes in the single-agent cabozantinib cohort were exploratory.

Results

Eighty-one patients assigned to combination therapy and 31 assigned to single-agent cabozantinib received greater than or equal to one dose of study treatment. Median (range) follow-up was 26.1 months (12.1–44.2) and 22.4 months (1.5–29.0), respectively. Objective response rate was 20% (95% confidence interval: 11.7%–30.1%) in combination cohort and 6% (95% confidence interval: 0.8%–21.4%) in single-agent cabozantinib cohort. Treatment-related adverse events (TRAEs) occurred in 86% of patients in the combination cohort and 90% in the single-agent cabozantinib cohort; grade 3/4 TRAEs were 44% and 48%, respectively. There were two grade 5 TRAEs: pneumonitis (n = 1, combination) and gastric ulcer hemorrhage (n = 1, single-agent). Neither PD-L1 expression in tumor cells nor tumor mutation burden correlated with outcomes.

Conclusions

Cabozantinib plus atezolizumab demonstrated modest clinical activity and manageable toxicity in advanced NSCLC after progression on prior ICI.

导言我们评估了卡博替尼加阿特珠单抗或卡博替尼单药治疗既往接受过免疫检查点抑制剂(ICI)治疗的晚期NSCLC的疗效和安全性。方法COSMIC-021(NCT03170960)是一项晚期实体瘤的1b期多中心研究。这项分析纳入了既往接受过一种 ICI 且既往接受过少于或等于两种全身抗癌疗法的 IV 期非鳞状 NSCLC 患者,这些患者的 EGFR、ALK、ROS1 或 BRAF-V600E 基因组无可操作性畸变。患者每天口服卡博替尼40毫克,每三周静脉注射atezolizumab 1200毫克(联合用药组)或每天口服卡博替尼60毫克(单药卡博替尼组)。联合用药队列的主要终点是研究者根据实体瘤反应评价标准 v1.1 确定的客观反应率。结果 81例接受联合治疗的患者和31例接受单药卡博替尼治疗的患者接受了大于或等于一个剂量的研究治疗。随访中位数(范围)分别为26.1个月(12.1-44.2)和22.4个月(1.5-29.0)。联合用药队列的客观应答率为20%(95%置信区间:11.7%-30.1%),单药卡博替尼队列的客观应答率为6%(95%置信区间:0.8%-21.4%)。联合用药队列中有86%的患者发生了治疗相关不良事件(TRAEs),单药卡博替尼队列中有90%的患者发生了治疗相关不良事件(TRAEs);3/4级TRAEs发生率分别为44%和48%。有两例5级TRAE:肺炎(1例,联合用药)和胃溃疡出血(1例,单药)。肿瘤细胞中的 PD-L1 表达和肿瘤突变负荷均与疗效无关。结论卡博赞替尼联合阿特珠单抗治疗既往 ICI 治疗进展后的晚期 NSCLC 表现出适度的临床活性和可控的毒性。
{"title":"Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study","authors":"","doi":"10.1016/j.jtocrr.2024.100666","DOIUrl":"10.1016/j.jtocrr.2024.100666","url":null,"abstract":"<div><h3>Introduction</h3><p>We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI).</p></div><div><h3>Methods</h3><p>COSMIC-021 (NCT03170960) is a phase 1b, multicenter study in advanced solid tumors. This analysis included patients with stage IV non-squamous NSCLC without actionable genomic aberrations in <em>EGFR, ALK, ROS1</em>, or <em>BRAF</em>-<em>V600E</em> who progressed on one prior ICI and less than or equal to two prior lines of systemic anticancer therapy. Patients received cabozantinib 40 mg orally/day plus atezolizumab 1200 mg intravenously every three weeks (combination cohort) or cabozantinib 60 mg orally/day (single-agent cabozantinib cohort). Primary end point of the combination cohort was objective response rate per Response Evaluation Criteria in Solid Tumors v1.1 by investigator. Outcomes in the single-agent cabozantinib cohort were exploratory.</p></div><div><h3>Results</h3><p>Eighty-one patients assigned to combination therapy and 31 assigned to single-agent cabozantinib received greater than or equal to one dose of study treatment. Median (range) follow-up was 26.1 months (12.1–44.2) and 22.4 months (1.5–29.0), respectively. Objective response rate was 20% (95% confidence interval: 11.7%–30.1%) in combination cohort and 6% (95% confidence interval: 0.8%–21.4%) in single-agent cabozantinib cohort. Treatment-related adverse events (TRAEs) occurred in 86% of patients in the combination cohort and 90% in the single-agent cabozantinib cohort; grade 3/4 TRAEs were 44% and 48%, respectively. There were two grade 5 TRAEs: pneumonitis (n = 1, combination) and gastric ulcer hemorrhage (n = 1, single-agent). Neither PD-L1 expression in tumor cells nor tumor mutation burden correlated with outcomes.</p></div><div><h3>Conclusions</h3><p>Cabozantinib plus atezolizumab demonstrated modest clinical activity and manageable toxicity in advanced NSCLC after progression on prior ICI.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 10","pages":"Article 100666"},"PeriodicalIF":3.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000365/pdfft?md5=8cbe6ed5619b31f78dc83383f890cb04&pid=1-s2.0-S2666364324000365-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140277898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC 简要报告:寡转移性 NSCLC 局部消融治疗后 Pembrolizumab 辅助治疗的长期随访
Q2 ONCOLOGY Pub Date : 2024-03-20 DOI: 10.1016/j.jtocrr.2024.100667
David J. Cantor MD, PhD , Christiana Davis MD , Christine Ciunci MD, MSCE , Charu Aggarwal MD, MPH , Tracey Evans MD , Roger B. Cohen MD , Joshua M. Bauml MD , Corey J. Langer MD

Introduction

Patients with oligometastatic NSCLC benefit from locally ablative therapies (LAT); the role of adjuvant systemic therapies, however, remains less clear. In a single-arm, phase II clinical trial, we found that patients with oligometastatic NSCLC treated with a year of pembrolizumab after LAT had superior progression-free survival (PFS) compared with a historical control cohort. Herein, we present long-term follow-up on PFS and overall survival (OS).

Methods

From February 1, 2015, to September 30, 2017, 45 patients with synchronous or metachronous oligometastatic (≤4 metastatic sites) NSCLC treated with LAT to all sites received adjuvant pembrolizumab every 21 days for up to 16 cycles. The primary efficacy end point was PFS from the start of pembrolizumab. Secondary end points included OS and safety. Median duration of follow-up was 66 months, and data cutoff was December 1, 2022.

Results

A total of 45 patients were enrolled and treated with pembrolizumab after LAT (median age, 64 y [range, 46–82]; 21 women [47%]; 31 with a solitary oligometastatic site [69%]). At the data cutoff, 32 patients had progressive disease, 19 patients had died, and 13 patients had no evidence of relapse. Median PFS was 19.7 months (95% confidence interval: 7.6–31.7 mo); median OS was not reached (95% confidence interval: 37.7 mo–not reached). OS at 5 years was 60.0% (SE, 7.4%). Metachronous oligometastatic disease was associated with improved OS and PFS through Cox proportional hazard models.

Conclusions

Pembrolizumab after LAT for oligometastatic NSCLC results in promising PFS and OS with a tolerable safety profile.

导言少转移性 NSCLC 患者可从局部消融治疗(LAT)中获益;然而,辅助性全身治疗的作用仍不十分明确。在一项单臂 II 期临床试验中,我们发现寡转移性 NSCLC 患者在局部消融治疗后接受一年的 pembrolizumab 治疗,其无进展生存期(PFS)优于历史对照组。方法从2015年2月1日至2017年9月30日,45名接受LAT治疗至所有部位的同步或近同步寡转移(≤4个转移部位)NSCLC患者接受了每21天一次的pembrolizumab辅助治疗,最多16个周期。主要疗效终点是开始使用 pembrolizumab 后的 PFS。次要终点包括OS和安全性。中位随访时间为66个月,数据截止日期为2022年12月1日。结果共有45名患者入组,并在LAT后接受了pembrolizumab治疗(中位年龄为64岁[46-82岁];21名女性[47%];31名患者为单发少转移部位[69%])。数据截止时,32 名患者病情进展,19 名患者死亡,13 名患者无复发迹象。中位 PFS 为 19.7 个月(95% 置信区间:7.6-31.7 个月);未达到中位 OS(95% 置信区间:37.7 个月-未达到)。5年的OS为60.0%(SE,7.4%)。通过 Cox 比例危险模型,近端寡转移性疾病与 OS 和 PFS 的改善相关。
{"title":"Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC","authors":"David J. Cantor MD, PhD ,&nbsp;Christiana Davis MD ,&nbsp;Christine Ciunci MD, MSCE ,&nbsp;Charu Aggarwal MD, MPH ,&nbsp;Tracey Evans MD ,&nbsp;Roger B. Cohen MD ,&nbsp;Joshua M. Bauml MD ,&nbsp;Corey J. Langer MD","doi":"10.1016/j.jtocrr.2024.100667","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100667","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with oligometastatic NSCLC benefit from locally ablative therapies (LAT); the role of adjuvant systemic therapies, however, remains less clear. In a single-arm, phase II clinical trial, we found that patients with oligometastatic NSCLC treated with a year of pembrolizumab after LAT had superior progression-free survival (PFS) compared with a historical control cohort. Herein, we present long-term follow-up on PFS and overall survival (OS).</p></div><div><h3>Methods</h3><p>From February 1, 2015, to September 30, 2017, 45 patients with synchronous or metachronous oligometastatic (≤4 metastatic sites) NSCLC treated with LAT to all sites received adjuvant pembrolizumab every 21 days for up to 16 cycles. The primary efficacy end point was PFS from the start of pembrolizumab. Secondary end points included OS and safety. Median duration of follow-up was 66 months, and data cutoff was December 1, 2022.</p></div><div><h3>Results</h3><p>A total of 45 patients were enrolled and treated with pembrolizumab after LAT (median age, 64 y [range, 46–82]; 21 women [47%]; 31 with a solitary oligometastatic site [69%]). At the data cutoff, 32 patients had progressive disease, 19 patients had died, and 13 patients had no evidence of relapse. Median PFS was 19.7 months (95% confidence interval: 7.6–31.7 mo); median OS was not reached (95% confidence interval: 37.7 mo–not reached). OS at 5 years was 60.0% (SE, 7.4%). Metachronous oligometastatic disease was associated with improved OS and PFS through Cox proportional hazard models.</p></div><div><h3>Conclusions</h3><p>Pembrolizumab after LAT for oligometastatic NSCLC results in promising PFS and OS with a tolerable safety profile.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 6","pages":"Article 100667"},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000377/pdfft?md5=0687f20c1fa0d78bc4ac583db50c81dd&pid=1-s2.0-S2666364324000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141068189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JTO Clinical and Research Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1